The Department of Veterans Affairs (VA) intends to award a sole-source contract for the procurement of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan), a radiopharmaceutical therapy for treating metastatic castration-resistant prostate cancer, to Advanced Accelerator Applications USA. This procurement falls under FAR 8.405-6(a)(1)(B), which permits contracting with a single source capable of providing the unique and specialized services required. The contract is classified under NAICS code 325412, with a size standard of 1,300 employees, emphasizing the VA's commitment to delivering specialized healthcare solutions for veterans. Interested parties must submit a tailored capability statement by 10:00 AM PT on October 29, 2024, to Hestia Sim at Hestia.Sim@va.gov, including relevant company details and qualifications, as the government reserves the right to proceed with the award without competition if no responses are received.